Publikationen (68) Publikationen von DAVID MARK EPSTEIN Verweis auf Forschungsdaten anzeigen.

2024

  1. A Systematic Review of the Impact of Spinal Cord Injury on Costs and Health-Related Quality of Life

    PharmacoEconomics - Open, Vol. 8, Núm. 6, pp. 793-808

  2. Economic assessment of abemaciclib for the adjuvant treatment of luminal HER2- breast cancer from the perspective of the Spanish health system

    European Journal of Health Economics

  3. Public Acceptance of Measures to Control Infectious Diseases Under Different Scenarios of Severity and Transmissibility

    Value in Health, Vol. 27, Núm. 5, pp. 562-569

2023

  1. Challenges for Economic Evaluations of Advanced Therapy Medicinal Products: A Systematic Review

    Value in Health, Vol. 26, Núm. 1, pp. 138-150

  2. Cost-effectiveness of Diagnostic Tools to Establish the Presence of Peripheral Arterial Disease in People with Diabetes

    Annals of Surgery, Vol. 277, Núm. 1, pp. E184-E191

  3. Cost-effectiveness of carotid endarterectomy in symptomatic patients

    The British journal of surgery, Vol. 110, Núm. 2, pp. 193-199

  4. Crónica del IX Taller de Evaluación Económica EEconAES

    Economía y salud: boletín informativo, Núm. 101, pp. 16-17

  5. Examining the benefit of graduated compression stockings in the prevention of hospital-associated venous thromboembolism in low-risk surgical patients: a multicentre cluster randomised controlled trial (PETS trial)

    BMJ open, Vol. 13, Núm. 1, pp. e069802

  6. INES: Interactive tool for construction and extrapolation of partitioned survival models

    Cost Effectiveness and Resource Allocation, Vol. 21, Núm. 1

  7. Meeting public health objectives and supporting the resumption of tourist activity through COVID-19: a triangular perspective

    Current Issues in Tourism, Vol. 26, Núm. 10, pp. 1617-1634

  8. Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries

    Frontiers in Pharmacology, Vol. 14

  9. The cost-effectiveness of a uniform versus age-based threshold for one-off screening for prevention of cardiovascular disease

    European Journal of Health Economics, Vol. 24, Núm. 7, pp. 1033-1045

2022

  1. Are costs derived from diagnosis-related groups suitable for use in economic evaluations? A comparison across nine European countries in the European Healthcare and Social Cost Database

    European Journal of Health Economics, Vol. 23, Núm. 9, pp. 1563-1575

  2. Barriers for the evaluation of advanced therapy medicines and their translation to clinical practice: Umbrella review

    Health Policy, Vol. 126, Núm. 12, pp. 1248-1255

  3. Comparing methods for handling missing cost and quality of life data in the Early Endovenous Ablation in Venous Ulceration trial

    Cost Effectiveness and Resource Allocation, Vol. 20, Núm. 1

  4. Cost-effectiveness analysis of current varicose veins treatments

    Journal of Vascular Surgery: Venous and Lymphatic Disorders, Vol. 10, Núm. 2, pp. 504-513.e7

  5. Development of the European Healthcare and Social Cost Database (EU HCSCD) for use in economic evaluation of healthcare programs

    BMC Health Services Research, Vol. 22, Núm. 1

  6. Evaluating the medical direct costs associated with prematurity during the initial hospitalization in Rwanda: a prevalence based cost of illness study

    BMC Health Services Research, Vol. 22, Núm. 1

  7. GACETA SANITARIA in 2021. Protecting the planet to protect health

    Gaceta Sanitaria

  8. How innovation can be defined, evaluated and rewarded in health technology assessment

    Health Economics Review, Vol. 12, Núm. 1